This company is on the right track imo except for two major obstacles; electroporation and plasmid technology. Electroporation is not conducive to vaccinations in the field. They also will have a problem with cold storage. Plasmids have been around for quite some time but it's old tech.
INO needs to find a way to make DNA without fermentation and another way to deliver the vaccines. If they can do that then I say the sky is the limit.
For now I see progress in some clinical trials but big roadblocks in advanced trials. There is still some time left for them to pivot before they become too wedded to the existing materials and methods currently outlined in the clinicals.
News 
Market Data 
Discover 
AI
